Notes / Company

Rekvina Laboratories Ltd.

REKVINA LAB. BSE 526075 ISIN INE092O01028 Pharmaceuticals

Fundamentals

Market cap: ₹21 cr
P/E: -85.83×
ROE: 41.27%
Debt / equity: -0.74
52-week range: 6.75 — 46.65

Research on Tijori Finance

The timeline — 1 note on Rekvina Laboratories Ltd.

May 2026

21 May 26 · 20:16 IST Brief

Brief · Earnings

Rekvina Laboratories generates its first revenue as losses persist

The nano-cap recorded ₹126.54 lakh in FY26 revenue while continuing to post a net loss of ₹25.47 lakh.

Verify on exchange BSE filings for REKVINA LAB. NSE filings for REKVINA LAB. Tijori Finance company page